Vanguard Capital Management
TARA icon

Vanguard Capital Management’s Protara Therapeutics TARA Stock Holding History

Vanguard Capital Management’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.79M Buy
2,300,133
+181,115
+9% +$861K ﹤0.01% 2899
2026
Q1 		$11M Buy
+2,119,018
New +$12.5M ﹤0.01% 2683

Other funds holding TARA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

Vanguard Capital Management's TARA Position: Q2 2026 in Review

Vanguard Capital Management increased its Protara Therapeutics (TARA) stake by 8.5% in Q2 2026, buying an estimated $861K and bringing the position to 2,300,133 shares worth $8.79M. The position accounts for ﹤0.01% of the portfolio, ranked #2899.

Vanguard Capital Management first reported a position in TARA in Q1 2026 and has held it in 2 quarters since. The position peaked at $11M in Q1 2026. 119 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

  • Vanguard Capital Management held 2,300,133 shares of Protara Therapeutics worth $8.79M as of Q2 2026.
  • Vanguard Capital Management bought 181,115 Protara Therapeutics shares in Q2 2026, an estimated $861K.
  • Protara Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2899 holding.
  • Vanguard Capital Management first reported a position in Protara Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Protara Therapeutics position peaked at $11M in Q1 2026.
  • 119 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.